CME Breakfast Symposium · Saturday, May 4, 2019 · Phoenix, AZ · 7:10 – 8:25am
Challenges and Advances in the Diagnosis and Management of Heart Failure with Preserved Ejection Fraction
Chaired by: JoAnn Lindenfeld, MD
Prognosis and treatment of heart failure patients with preserved ejection fraction (HFpEF) is complicated by diagnostic challenges and complicated pathophysiologies. Compared to HF patients with reduced ejection fraction (HFrEF), HFpEF patients are generally older, more often female, and have increased metabolic comorbidities such as obesity, hypertension, and type 2 diabetes mellitus. These metabolic comorbidities are associated with an increased risk of developing HFpEF, making the increase in metabolic syndrome in the recent decades particularly concerning. The lack of specific therapies for HFpEF have contributed to the increased prevalence and prognosis of the disease, and along with complicated diagnosis and pathophysiologies, contribute to the challenges that clinicians face in managing HFpEF. Advancements in disease pathophysiology, diagnostic tools, current and emerging treatment options may give clinicians additional tools to improve the outcomes of the disease; including morbidity, mortality, and quality of life.
To address these clinical practice gaps, expert faculty will focus on the latest evidence-based strategies to diagnose and manage HFpEF, including patients with comorbidities. This live symposium will also provide an overview on current and emerging resources and procedures designed to lower hospital readmission rates in HFpEF patients.
After completing this activity, the participant should be better able to:
Identify HFpEF based on current and emerging diagnostic approaches
Develop individualized treatment regimens for HFpEF patients with comorbidities based on current guidelines and evidence
Interpret the efficacy and safety of emerging treatment options and therapeutic strategies in HFpEF based on the latest clinical trial evidence
List approaches and resources aimed to improve hospital readmission rates for patients with HFpEF
This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Multi-supported by educational grants from Abbott and Novartis Pharmaceuticals Corporation.
This activity is approved for AMA PRA Category 1 Credits™
. This activity is eligible for ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on CMHC West, please click here.